Watson has voluntarily recalled one lot of fentanyl 75 mcg/hr patches due to the detection of leaking patches. At this time, no injuries have been reported in connection with the recalled lot but direct exposure to fentanyl gel may lead to serious adverse events, including respiratory depression and possible fatal overdose. No other strengths or lots were affected in this recall and no product shortage is anticipated.
Fentanyl transdermal patches are indicated for chronic pain management in opioid-tolerant patients who require continuous opioid analgesia and cannot be managed by lesser means (eg, acetaminophen-opioid combinations, NSAIDs, or as-needed dosing with short-acting opioids).
For more information call (888) 667-1508 or visit www.watson.com.